


Risk profiles and vaccine uptake in children
with invasive pneumococcal disease
at a tertiary hospital in Tshwane:

A retrospective review


Xandré Dearden

www.up.ac.za

***Streptococcus pneumoniae* incidence rate
per 100,000 children under five years of age, 2000**



Causes of under 5 childhood mortality in South Africa in 2000 and 2010



Method

- Retrospective descriptive analysis
- Pediatric wards of Kalafong Hospital in Tshwane.
- Younger than 13 years
- February 2009 until February 2013
- Positive culture for *S. pneumoniae* from a sterile site.



Results



Patient characteristics	N = 84 N(%)
Median age	36 months (6-4207)
Male:Female ratio	1.18:1
HIV positive	33 (51%)
CD4 count %	13.8% (0.8-35.6)
HIV status unknown	19 (23%)
Anthropometry done (admission)	58 (69%)
Underweight (<-2 z-score weight for age)	25 (43%)



- Tuberculosis was a comorbidity in 8/84 (9.5%)
- 13/76 (17%) missed primary PCV vaccine series
- Specimen source
 - Blood culture 48/69 (70%)
 - CSF 18/69 (26.1%)







Susceptibility by age group n/N(%)			
Penicillin susceptibility	< 1 year	1 – 5 years	> 5 years
Susceptible	13/35 (37%)	8/35 (23%)	14/35 (40%)
NON-susceptible	14/28 (50%)	13/28 (46%)	2/28 (7%)

Discussion

- Bacteraemia was the most common form of IPD identified at Kalafong hospital.
- HIV infection and malnutrition were two comorbid conditions found in up to half of cases.
- There was a decrease in the absolute number of IPD cases with PCV7 serotypes.
- Serotypes contained in the current 13-valent pneumococcal conjugate vaccine will protect against the most prevalent serotypes found.
- Ongoing surveillance of the antimicrobial resistance pattern will advise future policy on the recommended antibiotic strategy for pneumococcal infections

Take Home Message

- *Streptococcus pneumoniae* is still a major cause of death in children.
- HIV infection, TB and malnutrition are frequent co morbid conditions.
- Serotypes contained in the available 13-valent PCV will protect against the most prevalent serotypes found, thus emphasizing continued vaccine advocacy.



Recommendations

- Complete vaccine schedule
- Promote vaccination
- Catch up vaccines
- Investigate for TB and HIV
- Correct dose of antibiotics



**Keep calm,
this is
the end of
the
presentation.**

	Serotypes
Pneumovax	1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F
Prevnar	4, 6B, 9V, 14, 18C, 19F, 23F
Prevnar-13	1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F

- In private, the vaccine strains are decreasing
- 13 valent now covers strains most commonly found during 7 valent era.
- Serotype 1: shown to have distinct features such as prone to cause outbreaks(article in press)
- 3:1 more effective than 2:1
- Strains now in prevenar 13 use to be the strains previously resistant to ab.
- In practise, a fully vaccinated, uncomplicated patient, should not need broad spectrum or any ab when presenting with AOM.

Invasive Pneumococcal Disease in Children at a Tertiary Hospital in Tshwane, 2009 through 2013

CX Dearden¹, NM du Plessis¹, A von Gottberg², T Avenant¹

¹ Invasive Pneumococcal Disease in Children - Expanded Programme on Immunisation, University of Pretoria, South Africa
² National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa

Introduction

- *Streptococcus pneumoniae* disease still accounts for up to 1 million deaths in children <5 years.
- It remains an important cause of pneumonia, bacteraemia and meningitis worldwide.
- Vaccination is the main preventative strategy in young children.
- A pneumococcal conjugate vaccine is included in the Expanded Programme on Immunisation in South Africa.

Methods

- Retrospective chart-based analysis
- Laboratory confirmed IPD
- Children <13 years
- Kalafong Hospital
- February 2009 - February 2013
- Serotyping was done using Quellung method
- Resistance data were collected.
- Outcomes were documented

Results

➤ Eighty-four patients

Table 1 illustrates demographics and comorbidities

Table 1: Patient characteristics		N = 84
Age (days) (median; IQR)		60% (197 days) (6-4207)
Male/Female ratio		1:0.87
HIV positive		33 (51%)
HIV status unknown	CD4 cell count (%) (median; IQR)	13.8% (0.8-35.6)
Antituberculous drug administration		19 (23%)
Underweight (< -2 z-score weight-for-age)		26 (31%) 13 (50%)

- Tuberculosis was a comorbidity in only 6/84 (7%)
- 13/76 (17%) missed primary PCV vaccine series
- Specimen source
- Blood culture 48/69 (70%)
- CSF 18/69 (26.1%)
- Figure 1 shows serotype distribution for two periods since PCV7 introduction
- Serotypes 1(12/71, 16.9%), 23F (9/71, 12.7%), 6A (8/71, 11.3%) and 6B (7/71, 9.9%) were the most prevalent.

Discussion

Bacteraemia due to *Streptococcus pneumoniae* was the most common form of IPD identified at Kalafong hospital. HIV infection and malnutrition were two comorbid conditions found in up to half of cases. There was a decrease in the absolute number of IPD cases with PCV7 serotypes. Serotypes contained in the current 13-valent pneumococcal conjugate vaccine will protect against the most prevalent serotypes found, emphasising the need for continued vaccine advocacy. Ongoing surveillance of the antimicrobial resistance pattern will advise future policy on the recommended antibiotic strategy for pneumococcal infections

Important message...

- IPD remains an important disease in this setting
- HIV and malnutrition are significant cofactors
- Vaccination strategies should be supported

References

- Jeena PM. The burden of pneumococcal disease in children- advances in the fight of this epidemic. SA Fam Pract 2006;48(4): 29-30.
- Mehr S, Wood N. *Streptococcus pneumoniae* - a review of carriage, infection, serotype replacement and vaccination. Paediatric Respiratory Reviews 2012; 13(256-264).
- Von Gottberg A, Cohen C, De Gouveia L, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008. Vaccine 2013; 31:4200-4208.

Figure 1: Serotypes - Early vs Late PCV7 era

Table 2: Susceptibility by age group

Penicillin susceptibility	n/N (%)		
	< 1 year	1 - 5 years	> 5 years
Susceptible	13/36 (37%)	8/35 (23%)	14/38 (40%)
Non-susceptible	14/28 (50%)	13/28 (46%)	2/28 (7%)

University of Pretoria
Faculty of Health Sciences, Pretoria

Pediatric Infectious Diseases Division
University of Pretoria and Kalafong Hospital
Gauteng, South Africa
Dr. CX Dearden (cxdearden@gmail.com)
Supervisor: Dr. Nicolette du Plessis (nicollette.duplessis@up.ac.za)